| 0.0627 -0.002 (-3.54%) | 11-29 10:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.28 | 1-year : | 0.43 |
| Resists | First : | 0.24 | Second : | 0.37 |
| Pivot price | 0.15  |
|||
| Supports | First : | 0.02 | Second : | 0.02 |
| MAs | MA(5) : | 0.06  |
MA(20) : | 0.19 |
| MA(100) : | 0.4 |
MA(250) : | 0.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.7 |
D(3) : | 9.7 |
| RSI | RSI(14): 28.8 |
|||
| 52-week | High : | 2.17 | Low : | 0.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CMRA ] has closed above bottom band by 29.3%. Bollinger Bands are 140.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.07 - 0.07 | 0.07 - 0.07 |
| Low: | 0.06 - 0.06 | 0.06 - 0.06 |
| Close: | 0.06 - 0.07 | 0.07 - 0.07 |
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Tue, 21 Nov 2023
Comera Life Sciences Holdings, Inc.(OTCPK : CMRA) dropped from ... - Marketscreener.com
Mon, 13 Nov 2023
Comera Life Sciences Designates Dorothy Clarke to Board of ... - Yahoo Finance
Thu, 09 Nov 2023
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights - Yahoo Finance
Thu, 21 Sep 2023
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday’s Mid-D - Benzinga
Tue, 12 Sep 2023
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session - Aurora - Benzinga
Sat, 26 Aug 2023
These Are the ONLY 7 Penny Stocks to Consider in August 2023 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -3 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.074e+007 (%) |
| Held by Institutions | 1.218e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 422710 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.22 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 582.4 % |
| Return on Equity (ttm) | -119.4 % |
| Qtrly Rev. Growth | 629 % |
| Gross Profit (p.s.) | 95.58 |
| Sales Per Share | 187.12 |
| EBITDA (p.s.) | 352258 |
| Qtrly Earnings Growth | -7.55e+006 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.31 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 281550 |
| Forward Dividend | 27930 |
| Dividend Yield | 422114000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|